News & evidence
What is happening and how strong the evidence is: dates, congress readouts, approvals, failures, resistance, and the supply chain behind the drugs.
Where the evidence is published: scope, access model and the key papers each venue carried.
The papers that changed practice, each explained: what it found, what it means, what to be careful about.
Every trial ranked by evidence strength, endpoints as people out of 100.
Decisions, readouts, advisory committees, congresses.
ASCO, ESMO, AACR, ASCO GU, sourced item by item.
What did not work, and the lesson.
Escape routes per drug class and the countermeasures.
The chemistry inside ADCs.
Every dated filing, approval, CRL, and label change.
Medicare Part B or D, prior authorisation, list prices and assistance programmes for every approved product.
NICE, Cancer Drugs Fund and SMC decisions for every approved product, and how NHS cancer care works.
Which products are approved in the US, EU, UK, Japan, China and Australia, and which are missing where.
Fastest-growing topics in the literature, refreshed weekly from Europe PMC.
What the leading journals, regulators and news sources are saying this month.
Grade 3+ adverse events across products of the same class.
Lu-177, Ac-225, Pb-212 and who makes them.
The state of the war on cancer, year by year, generated from the corpus.
What changed in OnCo, and when.
Staleness, contradictions, and registry mismatches, recomputed each build.
Every factual correction, what was wrong and how it was found.